hub
md_pereligyn protocol, type 2 diabetes remission, HOMA-IR, metformin, berberine, GLP-1
Type 2 diabetes remission is statistics, not a myth. This hub collects evidence-based protocols for eliminating the root cause — insulin resistance. Topics: HOMA-IR and C-peptide diagnostics, metformin vs berberine, prediabetes reversal, the dark side of GLP-1 agonists (Ozempic), 500+ remission cases. Sources: Diabetes Care, Lancet Diabetes & Endocrinology, JAMA, Endocrine Reviews.
Last reviewed: 2026-06-01 · Dr. V. Pereligyn
Intermediate dysglycaemia defined by HbA1c 5.7–6.4%, fasting glucose 5.6–6.9 mmol/L, or 2-hour OGTT glucose 7.8–11.0 mmol/L. Prevalence exceeds 35% of adults. Hallmarks include insulin resistance and postprandial hyperinsulinaemia preceding overt fasting hyperglycaemia by years, often with normal routine lab panels.
Chronic metabolic disorder diagnosed at HbA1c ≥6.5%, fasting glucose ≥7.0 mmol/L, or 2-hour OGTT ≥11.1 mmol/L. Adult prevalence 10–12%. Pathogenesis combines insulin resistance with progressive β-cell dysfunction. Visceral adiposity and ectopic lipid deposition in liver and pancreas drive disease progression and complications.
Cluster of three or more criteria: waist circumference ≥94 cm (M)/≥80 cm (F), triglycerides ≥1.7 mmol/L, HDL <1.0/<1.3 mmol/L, blood pressure ≥130/85, fasting glucose ≥5.6 mmol/L. Prevalence 25–30%. Reflects systemic insulin resistance and multiplies cardiovascular risk severalfold even with normoglycaemia.
Reduced tissue insulin sensitivity with normal fasting glucose and HbA1c. Markers: HOMA-IR ≥2.5, fasting hyperinsulinaemia (>10 µIU/mL), exaggerated postprandial insulin response. Precedes prediabetes by 5–15 years. Detected through OGTT with paired glucose and insulin measurements, missed on standard fasting panels.
Maturity-Onset Diabetes of the Young is an autosomal-dominant monogenic diabetes presenting before age 25 with preserved C-peptide secretion. Accounts for 1–5% of diabetes cases. Most common subtypes: HNF1A (MODY3) and GCK (MODY2). Confirmed by genetic sequencing. Management differs from T2D — often insulin withdrawal in favour of sulfonylurea.
| Marker | Reference | What it means |
|---|---|---|
| HbA1c | <5.7% normal; 5.7–6.4% prediabetes; ≥6.5% diabetes | Reflects mean glycaemia over 8–12 weeks; falsely lowered by haemolysis and iron-deficiency anaemia. |
| Fasting insulin | 2.6–10.4 µIU/mL (target <8) | Values >10 indicate compensatory hyperinsulinaemia preceding hyperglycaemia by years. |
| HOMA-IR | <2.0 normal; 2.0–2.5 borderline; >2.5 insulin resistant | Formula: (insulin × glucose)/22.5; valid only with preserved β-cell function. |
| Fructosamine | 200–285 µmol/L | Glycated albumin reflecting 2–3 week glycaemia; useful when haemoglobinopathy invalidates HbA1c. |
| C-peptide | 0.9–7.1 ng/mL fasting | Quantifies residual β-cell secretion; low values suggest T1D or exhaustion, high values insulin resistance. |
| OGTT: glucose & insulin 0/120 min | glucose 120 min <7.8 mmol/L; insulin 120 min <60 µIU/mL | Paired test detects postprandial hyperinsulinaemia despite normal glucose. |
| AGE/RAGE (sRAGE) | individual, typically 500–1500 pg/mL | Low soluble RAGE correlates with accelerated vascular ageing and microvascular complications. |
Multicomponent regimen: caloric deficit 500–700 kcal/day with protein 1.6 g/kg, resistance training 3×/week, 16:8 intermittent fasting, metformin 1500–2000 mg and berberine 1500 mg/day at induction. Target: 10–15% body weight reduction and depletion of hepatic ectopic lipid. Author cohort observational data: 85% of patients with T2D duration <6 years achieve HbA1c <6.0% off glucose-lowering therapy within 12 months. Evidence level — observational, consistent with the DiRECT RCT remission paradigm. [1][2][3]
Berberine activates AMPK independent of insulin signalling and inhibits intestinal DPP-4, complementing metformin at the level of hepatic gluconeogenesis. Dosing: 500 mg three times daily with meals plus metformin 1000 mg twice daily. Meta-analysis of 27 RCTs (n=2569) reported HbA1c reduction of 0.7% beyond metformin alone, plus improved lipids and HOMA-IR. Berberine also mitigates metformin GI intolerance via microbiota modulation. Evidence quality — moderate, dominated by short Chinese RCTs. [1][2][3]
Semaglutide 0.25–2.4 mg/week subcutaneously lowers HbA1c by 1.5% and body weight by 10–15% over 68 weeks (STEP, SUSTAIN trials). Mechanism: delayed gastric emptying, central appetite suppression, glucose-dependent insulin secretion. Indicated as a bridge to metabolic restructuring, not as indefinite monotherapy. STEP-1 extension data: two-thirds of lost weight returns within one year of discontinuation. Strategy — gradual tapering paired with behavioural reinforcement. Evidence base — high-quality RCTs. [1][2][3]
A 14-day CGM (Libre, Dexcom) surfaces variability invisible to HbA1c. Key metrics: time in range 3.9–10.0 mmol/L >70%, coefficient of variation <36%, glucose management indicator. In non-diabetic subjects, postprandial peaks >7.8 mmol/L after a standard breakfast indicate early dysglycaemia. Applications: individualised diet titration, dawn phenomenon detection, glucose-lowering therapy assessment. Evidence base — RCTs for insulin-treated T1D and T2D; observational but clinically informative for prediabetes. [1][2][3]
A 47-year-old man, BMI 31.2, newly diagnosed type 2 diabetes: HbA1c 7.8%, fasting glucose 8.4 mmol/L, C-peptide 4.1 ng/mL, triglycerides 2.9 mmol/L, ALT 62 U/L. Treatment: metformin 1500 mg/day plus a structured nutrition program (carbohydrate restriction to 100 g/day, 500 kcal deficit), 10,000 steps/day, resistance training three times weekly. No GLP-1 agonist was used. At 4 months: HbA1c 5.6% (-2.2 percentage points), fasting glucose 5.3 mmol/L, weight loss 9.4 kg, triglycerides 1.3 mmol/L, ALT 28 U/L. Metformin tapered to 1000 mg/day. No hypoglycemia recorded.
A 36-year-old woman, PCOS phenotype A, BMI 28.6, waist circumference 92 cm. Labs: fasting insulin 19 µU/mL, glucose 4.9 mmol/L, HOMA-IR 4.2, total testosterone 2.8 nmol/L, SHBG 22 nmol/L, HbA1c 5.7%. Intervention: inositol (myo/D-chiro 40:1) 4 g/day, metformin 1000 mg/day, low-glycemic-load nutrition, aerobic exercise 150 min/week, sleep restoration to 7.5 hours. At 6 months: fasting insulin 6.4 µU/mL, HOMA-IR 1.1 (-3.1), waist circumference 81 cm, SHBG 48 nmol/L, HbA1c 5.2%. Ovulatory cycles restored; acne regressed.
Yes, when disease duration is <6 years and β-cell function is preserved (C-peptide >1.0 ng/mL), remission is achievable through 10–15% weight loss, depletion of hepatic ectopic lipid, and restored insulin sensitivity. The DiRECT RCT reported remission in 46% of participants at one year. The md_pereligyn protocol combines low-calorie diet, resistance training, metformin and berberine; HbA1c <6.0% is sustained off glucose-lowering therapy.
They are synergistic, not competing. Metformin is first-line with decades of evidence and proven cardiovascular protection. Berberine complements it via AMPK activation and microbiota modulation, adding 0.5–0.7% HbA1c reduction. Berberine does not replace metformin in established T2D but is useful in prediabetes and insulin resistance without hyperglycaemia, where metformin is not formally indicated. The combination outperforms either monotherapy.
HOMA-IR is the homeostatic model assessment of insulin resistance: (fasting insulin × fasting glucose)/22.5. Normal <2.0; >2.5 indicates significant insulin resistance. Sample strictly fasting 10–12 hours, in the morning, before exercise or coffee. Indicated for central obesity, PCOS, non-alcoholic fatty liver disease, and strong family history. In 30% of patients HOMA-IR >3 coexists with normal HbA1c — the index detects dysmetabolism years earlier.
Semaglutide mimics the gut hormone GLP-1: delays gastric emptying, suppresses hypothalamic appetite centres, and stimulates glucose-dependent insulin secretion. After discontinuation hunger signalling rebounds within 4–6 weeks while resting energy expenditure remains lowered post-weight loss. The STEP-1 extension showed two-thirds of lost weight regained within a year. Solution: gradual taper combined with behavioural reinforcement, not abrupt cessation.
For early dysglycaemia screening, a 14-day CGM is more informative than HbA1c. In 20–30% of individuals with normal HbA1c, postprandial peaks exceeding 10 mmol/L are recorded — an early marker of insulin resistance. CGM is valuable with strong family history of T2D, PCOS, central obesity, or prior gestational diabetes. For a metabolically healthy person without risk factors it is optional but reveals individual responses to specific foods and stress.
MODY is a monogenic, autosomal-dominant diabetes presenting before age 25. Unlike T1D, C-peptide is preserved and autoantibodies are absent; unlike T2D, there is no obesity or insulin resistance. Suspect it with three consecutive generations of diabetes, lean young onset, and excellent sulfonylurea response. Diagnosis is genetic sequencing (HNF1A, GCK, HNF4A). Accurate diagnosis discontinues unnecessary insulin in 90% of HNF1A-MODY patients.
The obesity pandemic cannot be explained by "eat less, move more" alone. Professor Bruce Blumberg of UC Irvine coined the term "obesogen" and demonstrated that hundreds of chemicals in food, plastics, and personal care products reprogram metabolism toward fat storage — with effects transmitted across generations.
GLP-1 receptor agonists like Ozempic have been hailed as miracle weight loss drugs. But behind the dramatic before-and-after photos lie serious risks — from irreversible stomach paralysis to losing muscle instead of fat.
Continuous glucose monitoring (CGM) has revolutionized diabetes management by providing real-time data instead of isolated fingerstick readings. We review the latest sensors, key metrics, and practical use cases.
Your doctor measures fasting glucose and HbA1c but never orders fasting insulin or calculates HOMA-IR. That's like checking temperature during pneumonia without doing a chest X-ray. Here's why this simple index is the key to early diagnosis.
She was 54, had lived with diabetes for 11 years, and was on four medications. They told her the disease was progressive. Five months later, her HbA1c was 5.4% — with zero medications.
"Can type 2 diabetes be cured?" — millions of people ask this question worldwide. Conventional medicine says no, only managed. But clinical research and practice tell a different story.
High blood sugar is a symptom, not the cause. The real problem is insulin resistance. While you fight symptoms, the disease progresses.
You're dieting, counting calories, but the weight won't budge. With type 2 diabetes, this is typical. The reason isn't a lack of willpower — it's a hormonal block.
Prediabetes affects 96 million Americans — one in three adults. The good news? It's the most reversible stage of metabolic dysfunction, with 95%+ success rates when caught early.
Dr. Pereligyn offers in-person and online consultations.
Book a consultation